|
|
|
|
LEADER |
02969nam a2200229Ia 4500 |
001 |
10-1161-JAHA-121-023277 |
008 |
220420s2022 CNT 000 0 und d |
020 |
|
|
|a 20479980 (ISSN)
|
245 |
1 |
0 |
|a Additive Effects of Genetic Interleukin-6 Signaling Downregulation and Low-Density Lipoprotein Cholesterol Lowering on Cardiovascular Disease: A 2×2 Factorial Mendelian Randomization Analysis
|
260 |
|
0 |
|b American Heart Association Inc.
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1161/JAHA.121.023277
|
520 |
3 |
|
|a BACKGROUND: Although trials suggest that anti-inflammatory approaches targeting interleukin (IL)-6 signaling can reduce cardiovascular risk, it remains unknown whether targeting IL-6 signaling could reduce risk additively to low-density lipoprotein cholesterol (LDL-C) lowering. Here, we assess interactions in associations of genetic downregulation of IL-6 signaling and LDL-C lowering with lifetime cardiovascular disease risk. METHODS AND RESULTS: Genetic scores for IL-6 signaling downregulation and LDL-C lowering were used to divide 408 225 White British individuals in UK Biobank into groups of lifelong exposure to downregulated IL-6 signaling, lower LDL-C, or both. Associations with risk of cardiovascular disease (coronary artery disease, ischemic stroke, peripheral artery disease, aortic aneurysm, vascular death) were explored in factorial Mendelian randomization. Compared with individuals with genetic IL-6 and LDL-C scores above the median, individuals with LDL-C scores lower than the median but IL-6 scores above the median had an odds ratio (OR) of 0.96 (95% CI, 0.93–0.98) for cardiovascular disease. A similar OR (0.96; 95% CI, 0.93–0.98) was estimated for individuals with genetic IL-6 scores below the median but LDL-C scores above the median. Individuals with both genetic scores lower than the median were at lower odds of cardiovascular disease (OR, 0.92; 95% CI, 0.90–0.95). There was no interaction between the 2 scores (relative excess risk attributed to interaction index, 0; synergy index, 1; P for multiplicative interaction=0.51). Genetic IL-6 score below the median was associated with lower cardiovascular disease risk across measured LDL-C strata (<100 or ≥100 mg/dL). CONCLUSIONS: Genetically downregulated IL-6 signaling and genetically lowered LDL-C are associated with additively lower lifetime risk of cardiovascular disease. Future trials should explore combined IL-6 inhibition and LDL-C lowering treatments for cardiovascular prevention. © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
|
650 |
0 |
4 |
|a Atherosclerosis
|
650 |
0 |
4 |
|a Inflammation
|
650 |
0 |
4 |
|a Interleukin-6
|
650 |
0 |
4 |
|a Low-density lipoprotein
|
650 |
0 |
4 |
|a Mendelian randomization
|
700 |
1 |
0 |
|a Burgess, S.
|e author
|
700 |
1 |
0 |
|a Dichgans, M.
|e author
|
700 |
1 |
0 |
|a Georgakis, M.K.
|e author
|
700 |
1 |
0 |
|a Malik, R.
|e author
|
773 |
|
|
|t Journal of the American Heart Association
|